Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The expression of interleukin-1-receptor antagonist is reduced in pancreatic islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of interleukin-1beta in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis. METHODS: In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, we randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant human interleukin-1-receptor antagonist) subcutaneously once daily for 13 weeks and 36 patients to receive placebo. At baseline and at 13 weeks, all patients underwent an oral glucose-tolerance test, followed by an intravenous bolus of 0.3 g of glucose per kilogram of body weight, 0.5 mg of glucagon, and 5 g of arginine. In addition, 35 patients underwent a hyperinsulinemic-euglycemic clamp study. The primary end point was a change in the level of glycated hemoglobin, and secondary end points were changes in beta-cell function, insulin sensitivity, and inflammatory markers. RESULTS: At 13 weeks, in the anakinra group, the glycated hemoglobin level was 0.46 percentage point lower than in the placebo group (P=0.03); C-peptide secretion was enhanced (P=0.05), and there were reductions in the ratio of proinsulin to insulin (P=0.005) and in levels of interleukin-6 (P<0.001) and C-reactive protein (P=0.002). Insulin resistance, insulin-regulated gene expression in skeletal muscle, serum adipokine levels, and the body-mass index were similar in the two study groups. Symptomatic hypoglycemia was not observed, and there were no apparent drug-related serious adverse events. CONCLUSIONS: The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation. (ClinicalTrials.gov number, NCT00303394 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [84]
In the citing paper
“improved glucose control required fewer glucose-lowering agents, including insulin”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“a greater proportion of participants achieved a HbA1c <7%135”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“A benefit for anakinra was also shown in a small, randomized trial of 70 patients with type 2 diabetes109.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
In the citing paper
“However, the clinical study was still small and was not designed to determine optimal dosing, duration of use or long-term outcomes in disease control.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationNeonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Cited by
Items 601–700 of 1,001
Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis
Henderson, C., & Goldbach‐Mansky, R. T. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32833ceff4 · Cited by 76
Beyond the Hormone: Insulin as an Autoimmune Target in Type 1 Diabetes
Brezar, V., Carel, J., Boîtard, C., & Mallone, R. (2011) · Endocrine Reviews · doi:10.1210/er.2011-0010 · Cited by 78
Therapeutic vaccines for chronic diseases: successes and technical challenges
Bachmann, M. F., & Jennings, G. T. (2011) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0103 · Cited by 70
Hung, A. M., Sundell, M. B., Egbert, P., Siew, E. D., Shintani, A., Ellis, C. D., Bian, A., & Ikizler, T. A. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08070910 · Cited by 69
Azcutia, V., Abu-Taha, M. I., Romacho, T., Vázquez-Bella, M., Matesanz, N., Luscinskas, F. W., Rodríguez‐Mañas, L., Sanz, M., Sánchez‐Ferrer, C. F., & Peiró, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010091 · Cited by 77
Ramos-Zavala, M. G., González-Ortiz, M., Martínez-Abundis, E., Robles-Cervantes, J. A., González-López, R., & Santiago-Hernández, N. J. (2011) · Diabetes Care · doi:10.2337/dc11-0357 · Cited by 68
Exercise tolls the bell for key mediators of low-grade inflammation in dysmetabolic conditions
Guardia, L. D., & Codella, R. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.09.003 · Cited by 70
“In obesity and T2D, white adipose tissue releases pro-inflammatory mediators affecting gluco-metabolic homeostasis by altering liver and muscle functionality [2,9].”
BackgroundInfluentialSustained Delivery of IL-1Ra from PF127-Gel Reduces Hyperglycemia in Diabetic GK-Rats
Akash, M. S. H., Rehman, K., Sun, H., & Chen, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055925 · Cited by 74
NLRP3 and IL ‐1 β in macrophages as critical regulators of metabolic diseases
McGettrick, A. F., & O'Neill, L. A. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12169 · Cited by 72
The multiple origins of Type 1 diabetes
Pugliese, A. (2013) · Diabetic Medicine · doi:10.1111/dme.12081 · Cited by 79
Damage-associated molecular patterns and their pathological relevance in diabetes mellitus
Shin, J. J., Lee, E. K., Park, T. J., & Kim, W. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.06.004 · Cited by 74
Prestwood, T. R., Asgariroozbehani, R., Wu, S., Agarwal, S. M., Logan, R. W., Ballon, J. S., Hahn, M., & Freyberg, Z. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113101 · Cited by 75
“Metabolic effects of common inflammatory mediators, selected studies Mediator Glucose Intolerance Insulin Resistance Weight Gain Inflammation First author, year Study Details IL-1Rα ↓ — — ↓ Larsen, 2007 T2DM patients treated with IL-1Rα IL-1β ↑ — ↑ Cavelti-Weder, 2012 T2DM patients treated with αIL-1β mAB IL-6 ↓ ↓ ↓ M…”
InfluentialEgbujor, M. C., Buttari, B., Profumo, E., Telkoparan‐Akillilar, P., & Saso, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158466 · Cited by 70
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker, P. M. (2013) · Europe PMC (PubMed Central) · Cited by 86
Stahel, M., Becker, M., Graf, N., & Michels, S. (2016) · Retina · doi:10.1097/iae.0000000000000701 · Cited by 67
Psoriasis and risk of diabetes-associated microvascular and macrovascular complications
Armstrong, A. W., Guérin, A., Sundaram, M., Wu, E. Q., Faust, E., Ionescu‐Ittu, R., & Mulani, P. M. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.02.1095 · Cited by 73
Inflammasomes: Key Mediators of Lung Immunity
Howrylak, J. A., & Nakahira, K. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105229 · Cited by 72
Obesity, diabetes, and inflammation: Pathophysiology and clinical implications
Donath, M. Y., & Drucker, D. J. (2025) · Immunity · doi:10.1016/j.immuni.2025.09.011 · Cited by 69
Self-citationRole of the Inflammasome in Myocardial Infarction
Takahashi, M. (2011) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2012.02.002 · Cited by 68
Demidowich, A. P., Davis, A. I., Dedhia, N., & Yanovski, J. A. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.04.039 · Cited by 68
Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors
Hill, J. R., Coll, R. C., Sue, N., Reid, J. C., Dou, J., Holley, C. L., Pelingon, R., Dickinson, J. B., Biden, T. J., Schroder, K., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700270 · Cited by 62
Meier, R. P. H., Meyer, J., Montanari, E., Lacotte, S., Balaphas, A., Muller, Y. D., Clément, S., Negro, F., Toso, C., Morel, P., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061295 · Cited by 65
“We observed a significant increase in fasting insulin levels in mice after BDL in WT mice and KO mice (consistent with insulin resistance that is commonly observed during liver fibrosis/dysfunction [55]), however that increase was completely reversed by IL-1Ra treatment in WT mice (and KO mice) (Supplementary Figure S…”
BackgroundInhibition of IL-1 β Improves Fatigue in Type 2 Diabetes
Cavelti-Weder, C., Furrer, R., Keller, C., Babians-Brunner, A., Solinger, A. M., Gast, H., Fontana, A., Donath, M. Y., & Penner, I. K. (2011) · Diabetes Care · doi:10.2337/dc11-1196 · Cited by 64
Self-citationLawrie, A., Hameed, A. G., Chamberlain, J., Arnold, N. D., Kennerley, A. J., Hopkinson, K., Pickworth, J. A., Kiely, D. G., Crossman, D. C., & Francis, S. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.06.037 · Cited by 65
The triad psoriasis–obesity–adipokine profile
Coimbra, S., Catarino, C., & Santos‐Silva, A. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13701 · Cited by 69
Cannito, S., Morello, E., Bocca, C., Foglia, B., Benetti, E., Novo, E., Chiazza, F., Rogazzo, M., Fantozzi, R., Povero, D., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172575 · Cited by 64
Update of inflammatory proliferative retinopathy: Ischemia, hypoxia and angiogenesis
Aouiss, A., Idrissi, D. A., Kabine, M., & Zaid, Y. (2019) · Current Research in Translational Medicine · doi:10.1016/j.retram.2019.01.005 · Cited by 72
Metabolic control and sex: A focus on inflammatory‐linked mediators
Henstridge, D. C., Abildgaard, J., Lindegaard, B., & Febbraio, M. A. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14642 · Cited by 72
Pathophysiology of Neurogenic Obesity After Spinal Cord Injury
Gater, D. R., Farkas, G. J., & Tiozzo, E. (2021) · Topics in Spinal Cord Injury Rehabilitation · doi:10.46292/sci20-00067 · Cited by 68
Javeed, N., Her, T. K., Brown, M., Vanderboom, P. M., Rakshit, K., Egan, A. M., Vella, A. V., Lanza, I. R., & Matveyenko, A. V. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109613 · Cited by 69
Cysteine 253 of UCP1 regulates energy expenditure and sex-dependent adipose tissue inflammation
Mills, E. L., Harmon, C., Jedrychowski, M. P., Xiao, H., Gruszczyk, A. V., Bradshaw, G. A., Tran, N., Garrity, R., Laznik-Bogoslavski, D., Szpyt, J., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.11.003 · Cited by 68
Lactobacillus plantarum OLL2712 Regulates Glucose Metabolism in C57BL/6 Mice Fed a High-Fat Diet
SAKAI, T., TAKI, T., NAKAMOTO, A., SHUTO, E., TSUTSUMI, R., TOSHIMITSU, T., MAKINO, S., & IKEGAMI, S. (2013) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.59.144 · Cited by 64
Survival in a bad neighborhood: pancreatic islets in cystic fibrosis
Norris, A. W., Ode, K. L., Merjaneh, L., Sanda, S., Yi, Y., Sun, X., Engelhardt, J. F., & Hull, R. L. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0468 · Cited by 69
Advanced Glycation End Products Enhance M1 Macrophage Polarization by Activating the MAPK Pathway
He, S., Hu, Q., Xu, X., Niu, Y., Chen, Y.-M., Lu, Y., Su, Q., & Qin, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.053 · Cited by 67
Nelson, S. M., Sattar, N., Freeman, D. J., Walker, J. D., & Lindsay, R. S. (2007) · Diabetes · doi:10.2337/db07-0662 · Cited by 63
Interleukin‐1 Family Cytokines in Liver Diseases
Tsutsui, H., Cai, X., & Hayashi, S. (2015) · Mediators of Inflammation · doi:10.1155/2015/630265 · Cited by 72
Endocannabinoid regulation of β ‐cell functions: implications for glycaemic control and diabetes
Jourdan, T., Godlewski, G., & Kunos, G. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12646 · Cited by 63
Hong, K.-H., Xu, G., Grayson, T. B., & Shalev, A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.698365 · Cited by 67
Physiological role of cytokines in the regulation of mammalian metabolism
Baat, A. D., Trinh, B., Ellingsgaard, H., & Donath, M. Y. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.06.002 · Cited by 64
Self-citationToshimitsu, T., Mochizuki, J., Ikegami, S., & Itou, H. (2015) · Journal of Dairy Science · doi:10.3168/jds.2015-9916 · Cited by 65
“Meanwhile, Larsen et al. (2007) and Osborn et al. (2008) demonstrated that blockage of IL-1β signaling improved glucose metabolism in randomized clinical trials and in diet-induced obesity mouse models.”
BackgroundThe Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study
Eder, L., Chandran, V., Cook, R. J., & Gladman, D. D. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.160861 · Cited by 65
Brénachot, X., Ramadori, G., Ioris, R. M., Veyrat‐Durebex, C., Altirriba, J., Aras, E., Ljubicic, S., Kohno, D., Fabbiano, S., Clément, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02074-2 · Cited by 64
Montecucco, F., Steffens, S., & Mach, F. (2008) · Mediators of Inflammation · doi:10.1155/2008/767623 · Cited by 76
Crosstalk between Macrophages and Pancreatic β-Cells in Islet Development, Homeostasis and Disease
Cosentino, C., & Regazzi, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041765 · Cited by 66
Pezhman, L., Tahrani, A. A., & Chimen, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.624184 · Cited by 69
Jonas, M., Kurylowicz, A., Bartoszewicz, Z., Lisik, W., Jonas, M., Wierzbicki, Z., Chmura, A., Pruszczyk, P., & Puzianowska-Kuznicka, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025817 · Cited by 61
Obesity-related immune responses and their impact on surgical outcomes
Quante, M., Dietrich, A., Elkhal, A., & Tullius, S. G. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.21 · Cited by 62
Inflammatory Cytokines and the Risk of Cardiovascular Complications in Type 2 Diabetes
Mahmoud, F. F., & Al‐Ozairi, E. (2013) · Disease Markers · doi:10.1155/2013/931915 · Cited by 62
Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes
Spohn, G., Schori, C., Keller, I., Sladko, K., Sina, C., Guler, R., Schwarz, K., Johansen, P., Jennings, G. T., & Bachmann, M. F. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.48 · Cited by 63
Latent Inflammation and Insulin Resistance in Adipose Tissue
Stafeev, I. S., Vorotnikov, A. V., Ratner, E. I., Menshikov, M. Y., & Parfyonova, Y. V. (2017) · International Journal of Endocrinology · doi:10.1155/2017/5076732 · Cited by 57
Activation of NLRP3 Inflammasome by Advanced Glycation End Products Promotes Pancreatic Islet Damage
Kong, X., Lu, A., Yao, X.-M., Hua, Q., Li, X.-Y., Li, Q., Zhang, H., Meng, G., & Su, Q. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9692546 · Cited by 61
Jones, H. B., Nugent, D., & Jenkins, R. P. (2010) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2010.00713.x · Cited by 64
“…effects of IL1-b by antibody administration in hyperglycaemic, diet induced obese mice (Osborn et al. 2008) and an IL1-b antagonist in type II diabetic patients (Larsen et al. 2007) resulted in improved glycaemic control and b-cell function with lowered circulating inflammatory markers.”
BackgroundDinarello, C. A. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22841 · Cited by 61
Anti‐CD3 mAbs for treatment of type 1 diabetes
Kaufman, A. C., & Herold, K. C. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.933 · Cited by 60
Regulation of interleukin 1α secretion by inflammasomes
Yazdi, A. S., & Drexler, S. K. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202252 · Cited by 67
Adipose tissue at the nexus of systemic and cellular immunometabolism
Kohlgruber, A. C., LaMarche, N. M., & Lynch, L. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.09.005 · Cited by 60
Rahman, M. H., Bhusal, A., Lee, W., Lee, I., & Suk, K. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.024 · Cited by 61
Metaflammation in glucolipid metabolic disorders: Pathogenesis and treatment
Xiong, P., Zhang, F., Liu, F., Zhao, J., Huang, X., Luo, D., & Guo, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114545 · Cited by 59
Sauter, N. S., Thienel, C., Plutino, Y., Kampe, K., Dror, E., Traub, S., Timper, K., Bédat, B., Pattou, F., Kerr-Conte, J., et al. (2015) · Diabetes · doi:10.2337/db14-1282 · Cited by 59
Self-citationBöni‐Schnetzler, M., Ehses, J. A., Faulenbach, M. V., & Donath, M. Y. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00950.x · Cited by 63
Self-citationBecattini, B., Marone, R., Zani, F., Arsenijevic, D., Seydoux, J., Montani, J.-P., Dulloo, A. G., Thorens, B., Preitner, F., Wymann, M. P., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106698108 · Cited by 59
Death and Dysfunction of Transplanted β-Cells: Lessons Learned From Type 2 Diabetes?
Potter, K., Westwell-Roper, C., Klimek-Abercrombie, A., Warnock, G., & Verchere, C. (2013) · Diabetes · doi:10.2337/db12-0364 · Cited by 57
Regulation of Nlrp3 inflammasome by dietary metabolites
Camell, C. D., Goldberg, E. L., & Dixit, V. D. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.10.004 · Cited by 70
Midha, A., Pan, H., Abarca, C., Andle, J., Carapeto, P., Bonner-Weir, S., & Aguayo-Mazzucato, C. (2021) · Diabetes · doi:10.2337/db20-0553 · Cited by 58
Frankowski, R., Kobierecki, M., Wittczak, A., Różycka-Kosmalska, M., Pietras, T., Sipowicz, K., & Kosmalski, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119677 · Cited by 58
Akash, M. S. H., Rehman, K., Sun, H., & Chen, S. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.008 · Cited by 58
“As for as the matter of IL-1Ra concerned, many studies have been conducted on it (Larsen et al., 2007; Movassat et al., 2008; Sauter et al., 2008; Lacraz et al., 2009, Ehses et al., 2009) and none of these studies have reported any serious side effects in treatment groups except only few immune reactions at the site o…”
BackgroundResultMetaflammatory responses during obesity: Pathomechanism and treatment
Debnath, M., Agrawal, S., Agrawal, A., & Dubey, G. P. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.10.012 · Cited by 60
“Positive metabolic results including improved glycemic index and increased insulin secretion from the cells have been achieved as mentioned in a study using recombinant IL-1 receptor anatagonist [106].”
BackgroundCabrera, S. M., Wang, X., Chen, Y., Jia, S., Kaldunski, M. L., Greenbaum, C. J., the Type 1 Diabetes TrialNet Canakinumab Study Group, Mandrup‐Poulsen, T., the AIDA Study Group, & Hessner, M. J. (2016) · European Journal of Immunology · doi:10.1002/eji.201546005 · Cited by 56
Self-citationMacrophage heterogeneity and energy metabolism
Verdeguer, F., & Aouadi, M. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.043 · Cited by 64
Rymer, J. A., & Newby, L. K. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.07.001 · Cited by 65
Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance
Su, W.-J., Peng, W., Gong, H., Liu, Y.-Z., Zhang, Y., Lian, Y.-J., Cao, Z.-Y., Wu, R., Liu, L.-L., Wang, B., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0985-4 · Cited by 54
Inflammasomes and Cell Death: Common Pathways in Microparticle Diseases
Rashidi, M., Wicks, I. P., & Vince, J. E. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.06.005 · Cited by 60
Evans‐Molina, C., Hatanaka, M., & Mirmira, R. G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12163 · Cited by 55
Inflammation in psychotic disorders: A population-based study
Suvisaari, J., Loo, B.-M., Saarni, S. E., Haukka, J. K., Perälä, J., Saarni, S. I., Viertiö, S., Partti, K., Lönnqvist, J. K., & Jula, A. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.07.006 · Cited by 63
“IL-1RA is upregulated in acute inflammatory processes, in metabolic and cardiovascular diseases and in obesity (Larsen et al., 2007; Fearon and Fearon, 2008; Cartier et al., 2009).”
BackgroundT Cells in Adipose Tissue in Aging
Kalathookunnel Antony, A., Lian, Z., & Wu, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02945 · Cited by 56
“The major cytokines produced by Th2 cells, eosinophils, and ILC2 cells during type 2 immune response are IL-4, IL-5, and IL-13 (81, 82), which may promote the proliferation and differentiation of PDGFRα+ adipose stromal precursor cells to thermogenic beige adipocytes and therefore help to maintain thermogenesis in you…”
BackgroundInfluentialvan Poppel, P. C. M., van Asseldonk, E. J. P., Holst, J. J., Vilsbøll, T., Netea, M. G., & Tack, C. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12357 · Cited by 58
“Blocking the effects of IL-1 in patients with type 2 diabetes mellitus by anakinra, a recombinant human IL-1Ra, has been shown to improve glycaemic control through enhanced β cell function [6].”
BackgroundResultGupta, P., Sharma, G., Lahiri, A., & Barthwal, M. K. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.3a0620-348rr · Cited by 60
Ritter, M., Straubinger, K., Schmidt, S., Busch, D. H., Hagner, S., Garn, H., da Costa, C. P., & Layland, L. E. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12400 · Cited by 59
Giacomelli, R., Ruscitti, P., Alvaro, S., Ciccia, F., Liakouli, V., Benedetto, P. D., Guggino, G., Berardicurti, O., Carubbi, F., Triolo, G., et al. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1168293 · Cited by 57
Martins, F. M., Souza, A. D. P., Nunes, P. R. P., Michelin, M. A., Murta, E. F. C., Resende, E. A. M. R., de Oliveira, E. P., & Orsatti, F. L. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.02.016 · Cited by 63
“Moreover, inhibition of IL-1β by anakinra (a recombinant human IL-1ra) improves beta-cell dysfunction and glucose homeostasis in individuals with TDM2 (Larsen et al., 2007).”
BackgroundImmunosuppressive treatment and the risk of diabetes in rheumatoid arthritis
Lillegraven, S., Greenberg, J. D., Reed, G. W., Saunders, K., Curtis, J. R., Harrold, L., Hochberg, M. C., Pappas, D. A., Kremer, J. M., & Solomon, D. H. (2019) · PLOS ONE · doi:10.1371/journal.pone.0210459 · Cited by 54
“Blockade of interleukin-1 with the drug anakinra has been shown to improve glycemia and beta-cell secretory function in patients with type 2 diabetes [12].”
BackgroundObesity and metabolic inflammation
Xu, H. (2013) · Drug Discovery Today: Disease Mechanisms · doi:10.1016/j.ddmec.2013.03.006 · Cited by 57
The outliers become a stampede as immunometabolism reaches a tipping point
Nikolajczyk, B. S., Jagannathan‐Bogdan, M., & Denis, G. V. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01142.x · Cited by 58
Oligomerized CARD16 promotes caspase‐1 assembly and IL‐1β processing
Karasawa, T., Kawashima, A., Usui, F., Kimura, H. J., Shirasuna, K., Inoue, Y., Komada, T., Kobayashi, M., Mizushina, Y., Sagara, J., et al. (2015) · FEBS Open Bio · doi:10.1016/j.fob.2015.04.011 · Cited by 58
Caspases and inflammasomes in metabolic inflammation
Skeldon, A. M., Faraj, M., & Saleh, M. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.5 · Cited by 61
The Pancreatic β Cells in Human Type 2 Diabetes
Marchetti, P., Bugliani, M., Boggi, U., Masini, M., & Marselli, L. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_22 · Cited by 68
Bifunctional role of pro-inflammatory cytokines after traumatic brain injury
Sordillo, P. P., Sordillo, L. A., & Helson, L. (2016) · Brain Injury · doi:10.3109/02699052.2016.1163618 · Cited by 59
Ballak, D. B., Li, S., Cavalli, G., Stahl, J. L., Tengesdal, I. W., van Diepen, J. A., Klück, V., Swartzwelter, B. J., Azam, T., Tack, C. J., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003698 · Cited by 58
“hemoglobin A1C, a measure of elevated blood sugar, is reduced compared with placebo-treated subjects (20).”
BackgroundSelf-citationHepprich, M., Wiedemann, S. J., Schelker, B. L., Trinh, B., Stärkle, A., Geigges, M., Löliger, J., Böni-Schnetzler, M., Rudofsky, G., & Donath, M. Y. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.013 · Cited by 52
Self-citationSchwarznau, A., Hanson, M. S., Sperger, J. M., Schram, B. R., Danobeitia, J. S., Greenwood, K. K., Vijayan, A., & Fernandez, L. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21770 · Cited by 55
“…Rydgren et al., 2006) However, unlike the IL-1ra used in previous studies, Anakinra is a U.S. FDA approved drug which has been evaluated as an anti-inflammatory therapy in clinical trials of human subjects with rheumatoid arthritis (Botsios et al., 2007) and type 2 diabetes (Larsen et al., 2007).”
MethodEffects of anti-inflammatory therapies on glycemic control in type 2 diabetes mellitus
Li, D., Zhong, J., Zhang, Q., & Zhang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125116 · Cited by 64
“Anakinra, a recombinant human IL-1bR antagonist, can significantly reduce the level of HbA1c and may improve glycemic control by increasing insulin secretion (18).”
BackgroundBae, G. D., Park, E., Kim, K., Jang, S., Jun, H., & Oh, Y. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-53278-z · Cited by 68
Buler, M., Aatsinki, S., Skoumal, R., Komka, Z., Tóth, M., Kerkelä, R., Georgiadi, A., Kersten, S., & Hakkola, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.302356 · Cited by 62
Matsuura, E., Lopez, L. R., Shoenfeld, Y., & Ames, P. R. J. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.04.003 · Cited by 53
Osborn, O., Gram, H., Zorrilla, E., Conti, B., & Bartfai, T. (2008) · Swiss Medical Weekly · doi:10.4414/smw.2008.12276 · Cited by 64
Koppe, S., Elias, M. S., Moseley, R. H., & Green, R. M. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90543.2008 · Cited by 57
Inflammatory markers in children and adolescents with type 2 diabetes mellitus
Reinehr, T. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.07.006 · Cited by 56
Reappraising the stereotypes of diabetes in the modern diabetogenic environment
Wentworth, J. M., Fourlanos, S., & Harrison, L. C. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.149 · Cited by 57
“A recombinant IL-1 receptor antagonist improved insulin secretion and glucose tolerance in patients with T2DM, but did not alter the severity of systemic insulin resistance, which implies a role for IL-1β in the β-cell dysfunction associated with this disease”
BackgroundNLR‐containing inflammasomes: Central mediators of host defense and inflammation
Fitzgerald, K. A. (2010) · European Journal of Immunology · doi:10.1002/eji.201040331 · Cited by 52
Seijkens, T. T. P., Kusters, P. J. H., Engel, D. A., & Lutgens, E. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112455817 · Cited by 57
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y.
- Affiliations
- University Hospital Zurich (CH)
- Steno Diabetes Centers (DK)
- University of Zurich (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1517-1526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2024378513
- Cited by
- 1,798
- References
- 29
- Citations by year
- 2026: 41 · 2025: 47 · 2024: 61 · 2023: 75 · 2022: 89 · 2021: 97 · 2020: 84 · 2019: 83 · 2018: 87 · 2017: 77 · 2016: 111 · 2015: 113 · 2014: 135 · 2013: 141 · 2012: 132
- FWCI
- 93.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- anakinra, interleukin-1 receptor antagonist, type 2 diabetes, IL-1β, beta-cell function, insulin secretion, HbA1c, systemic inflammation, interleukin-6, C-reactive protein, C-peptide, hyperinsulinemic-euglycemic clamp, insulin resistance, adipokines
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gene Expression Regulation, Glucose Tolerance Test, Heat-Shock Proteins, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Middle Aged, Recombinant Proteins, RNA, Messenger, Transcription Factors, Interleukin-6, Body Mass Index, Receptors, Interleukin-1, Insulin-Secreting Cells, Glucose Transporter Type 4, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.